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esponsibility of InstAbstract The objective of the present work was to develop a metered dose transdermal spray (MDTS)
formulation for transdermal delivery of testosterone and to characterize its efﬁcacy. Testosterone release
from a series of formulations was assessed in vitro. Skin from hairless mice was used in permeation
experiments with Franz diffusion cells. The spray pattern, pump seal efﬁciency, average weight per
metered dose and dose uniformity were evaluated. An optimized formulation containing 10% (w/v)
testosterone, 9% (v/v) azone and 91% (v/v) ethanol was based on good skin permeation and acceptable
drug concentration and permeation enhancer (PE) content. A skin irritation study indicated that the
formulation was non-irritating in a rat model. An in vivo pharmacokinetic study indicated that the
optimized formulation showed a different plasma concentration-time proﬁle from that of the commercially
available product Testopatchs. The Testopatchs product demonstrated a more sustainable drug release.
The evaluation of the testosterone MDTS indicated that it could deliver reproducible amounts of the
formulation per actuation. The results obtained showed that the MDTS is a potential alternative
therapeutic system for transdermal testosterone delivery.
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Testosterone is the major circulating male androgen1. Testosterone
deﬁciency is usually associated with adverse effects on body composi-
tion, bone density, sexual function and mood, and may also increase
cardiovascular risk. Numerous studies have demonstrated the beneﬁts
of testosterone replacement in men with overt hypogonadism. Amongst
several possible administration routes for testosterone replacement, a
transdermal drug delivery system (TDDS) offers advantages over oral
and intramuscular application. Hepatic ﬁrst-pass metabolism in the liver
after oral administration requires high testosterone doses, and
potentially painful injections may lead to supra-physiological testos-
terone serum concentrations2. The relatively low molecular weight
(MW¼288) and moderate lipophilicity (log Po/w¼3.3; water
solubility¼0.039 mg/mL at 37 1C) of testosterone are favorable
factors for transdermal delivery3,4.
Gels, creams and patches are the most commonly used dosage
forms for TDDS5. Currently, gel and patch formulations (e.g.,
Androgels, Testoderms and Androderms) are used clinically.
However, a gel formulation has to be applied over large surface
areas to achieve the target plasma levels, and transfer of the drug
to female partners has been recorded. Although the approved
transdermal patches can avoid this problem, they have other
drawbacks which signiﬁcantly reduce patient acceptance and
compliance because of skin irritation caused by occlusion6. The
development of alternative formulations for the transdermal
delivery of testosterone remains a desirable goal7.
MDTS, which is quick drying and non-occlusive, is a better
alternative to both the patch and gel systems for easy application
and good tolerance. Moreover, the spray can form a “patchless
drug reservoir” on the skin8. MDTS formulations are topical
aerosols formulated as single phase solutions consisting of drug,
penetration enhancers and polymers9.
The aim of this work was to develop a safe MDTS formulation for
testosterone. In vitro drug release was evaluated using skin from the
hairless mouse, and the primary mechanism of drug delivery was
investigated. The pharmacokinetic proﬁle was evaluated by comparing
the pharmacokinetic parameters of the optimal formulation with that of
commercial product Testopatchs. The developed spray formulations
were further evaluated for their performance characteristics including
spray pattern, pump seal efﬁciency, average weight per metered dose
and content per spray. A skin irritation study also was carried out using
rat as an animal model.2. Materials and methods
2.1. Materials
Testosterone was supplied by Zizhu Pharma Co., Ltd. (Beijing,
China). Polyacrylic resin (Eudragits RL PO and Eudragits E PO)
were procured from Degussa (Germany). Polyvinyl pyrrolidone/
vinyl acetate (Plasdones S-630) and N-methyl-2-pyrrolidone
(NMP) were supplied by International Specialty Products (USA).
Polyvinylpyrrolidone (PVP K30) was kindly provided by BASF
(France). PEG 200, propylene glycol (PG) and ethanol were
purchased from Sino Pharma Chemicals Co., Ltd. (Shanghai,
China). Azone was purchased from Kejie Pharma Co., Ltd.
(Tianmen, Hubei, China). Isopropyl myristate (IPM) was provided
by Uniqema (UK). All other chemicals and solvents were of
analytical reagent grade or chromatography reagent grades.2.2. Solubility studies
Excess testosterone was added to different solvents10 and the
resulting suspensions were shaken at 2571.0 1C for 72 h. After
removal from the shaker bath, the equilibrated samples were
centrifuged for 3 min at 17,800 g. The supernatant was ﬁltered
(pore size: 0.22 mm) prior to further examination. The sample was
diluted such that the concentration was within the detection range
of the instrument. Saturated concentrations were determined for
each solution by HPLC using the method described below.
2.3. Formulation preparation
The MDTS formulations were developed as topical solutions made
up of volatile and non-volatile vehicles containing the drug
dissolved in a single phase. The non-volatile vehicle contains
only permeation enhancer (PE) or combination of PE and ﬁlm
forming polymer (FFP). The spray system was prepared by
incorporating FFP and PE into the solvent system. We used
ethanol as the volatile vehicle in this study. The drug application
system (Wantong Fixed Quantity Valve System Co., Ltd., Suzhou,
China) consisted of a 10 mL container and an actuator with an
actuating volume of 100 mL. Formulations were prepared with a
series of batches using different PEs or FFPs (Table 1). The
selection of optimum FFP was based on drying time, cosmetical
attractiveness and outward stickiness of the ﬁlm formed11. And the
selection of PE was based on transparency and non-volatility.
2.4. Characterization of the developed MDTS formulation
The characterization performed for the MDTS formulations
included the evaluation of the spray pattern, effectiveness of the
pump seal, average weight per metered dose and content uni-
formity12. The spray pattern was assessed by delivering the spray
through the MDTS onto paper. The formulation was held at a
distance of 5 cm from the paper. The wet part formed was
outlined, then the outlined part was clipped from the paper. The
area of the pattern was determined. Effectiveness of the pump seal
was evaluated by a pump seal efﬁciency test. The ﬁlled containers
were placed in the upright position at 301 for 3 days. The
containers were weighed before and after the test period.
The change in the weight of the container was recorded and the
leakage rates were calculated. Average weight per metered dose
was also measured. The initial weight of the container was
recorded, and the container was weighed again after successive
deliveries were sprayed from the MDTS. The difference between
the initial and ﬁnal weight of the container divided by the number
of deliveries sprayed from the containers was used to represent the
average weight per metered dose. The drug content per spray was
determined by actuating ten sprays in a beaker containing
methanol. This solution was shaken for 10 min and the drug
content was analyzed by HPLC. Content uniformity was assessed
by analyzing the drug content in 5th, 10th, 20th, 30th and 50th
doses emitted from the pump.
2.5. In vitro skin permeation experiments
2.5.1. Skin isolation and preparation
Hairless mice weighing 2272 g provided by the SLAC Labora-
tory Animal Company Ltd. (Shanghai, China) were used.
All animal studies were performed in accordance with Ethical
Table 2 Skin irritation score scale.
Grading Description of irritant response
0 No reaction
þ Weakly positive reaction (usually characterized by
mild erythema across most of the treatment site)
þ þ Moderate positive reaction (usually distinct erythema
possibly spreading beyond the treatment site)
þþþ Strongly positive reaction (strong, often spreading
erythema with odema)
Table 1 Composition of investigated formulations.
Ingredient (% w/v) F1 F2 F3 F4 F5 F6 F7 F8 F9c
Testosterone 5 5 5 5 5 5 5 5 5
PEa – – – – 5 5 5 5 0
FFPb 5 5 5 5 0 0 0 0 0
Absolute alcohol Add to 10 mL
aPEs used in F5–F8 were azone, IPM, NMP and PG, respectively.
bFFPs used in F1–F4 were Eudragits E PO, Eudragits RL PO, Plasdones S630 and PVP K30, respectively.
cF9 was used as the control group.
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approved by National Pharmaceutical Engineering and Research
Center. The dorsal skin was excised after the mice were killed by
cervical dislocation. Fresh prepared skin was stored in the freezer
at 20 1C without repeatable freeze and thaw recycles. Prior to
permeation experiments, the skin was thawed and subcutaneous
fat, tissue and capillaries of the skin were carefully removed. After
cutting into pieces, the skin was mounted between the donor and
receptor compartment of the Franz diffusion cells with the stratum
corneum facing the donor compartment.
2.5.2. Permeation studies
The permeation area of Franz diffusion cells was 3.14 cm2 and the
receiver volume was 7.0 mL. 40% PEG 200 was used as the receiver
medium. Assembled diffusion cells in triplicate were placed in a
transdermal permeation diffusion instrument and maintained isother-
mally at 32 1C. The receptor compartment was stirred with a magnetic
stirrer at 220 rpm. The air bubbles that remained in the receptor cell
were carefully removed by gentle tilting of the diffusion cells. Since the
drug administration area is about 12 cm2 (in bioequivalence study) for
each pump, we used a micropipette to delivery 50 mL drug solution
precisely in order to mimic the true situation of drug administration and
the uniformity of drug on the skin sample. In the experiments for PE
screening we applied 100 mL drug solution in order to amplify the
effect of PE for observation. The system was maintained at 32 1C for
2 h. Samples of 0.3 mL were withdrawn at 2, 4, 6, 8, 10 and 24 h for
HPLC analysis and an equivalent volume was added to the system to
supplement the volume loss. After centrifugation at 17,800 g for
3 min, the supernatant was used for analysis.
2.6. In vivo animal experiments
Healthy female Sprague-Dawley rats weighing 220720 g provided by
the SLAC Laboratory Animal Company Ltd. (Shanghai, China) were
used in this study. The animals were housed four per cage in laminar
ﬂow that were maintained at 2272 1C and relative humidity of
50–60%. The animals were kept in these facilities for at least 1 week
prior to the experiment and were fasted for at least 24 h before
commencing the experiments. Before administration, the abdominal
hair was shaved using an electric clipper carefully and allowed to heal
for 24 h. The animals were divided into three groups with four animals
in each group. The ﬁrst and second groups were given the testosterone
MDTS or the Testopatchs, respectively. The remaining group did not
receive any treatment and served as the control group. Blood samples
(250–300 mL) were collected via the retro-orbital plexus using a
sterilized glass capillary tube. Before the experiments, blood samples
of 300 mL were taken to measure the basal level of endogenous
testosterone in each rat. After application of testosterone MDTS or theTestopatchs, blood samples were collected at the scheduled sampling
times. The blood samples of rats in the control group were also
collected to record the level of endogenous testosterone during the
experiment. After centrifugation at 17,800 g for 3 min, the separated
serum of 100 mL was transferred into another neat tube and frozen at
20 1C until the determination of testosterone concentration by
UPLC–MS/MS analysis.
2.7. Skin irritation study
The Draize patch test was carried out using rats as the animal
model13. The optimized formulation was sprayed on the patch of
shaven skin and occluded with adhesive tapes and the resulting
reactions such as erythema and edema were scored after 24 h. The
skin irritation score scale is shown in Table 2.
2.8. Analytical method
2.8.1. HPLC analysis
The samples of testosterone in the in vitro experiments were
analyzed using a HPLC system consisting of a system controller
(SCL-10 ATVP; Shimadzu, Japan), a binary pump (LC-10 ATVP,
Shimadzu), a UVVis detector (SPD-10 AVP, Shimadzu), a
column oven and an auto injector (SIL-10A, Shimadzu). The
separation was obtained through a C18 reversed phase analytical
column (150 mm 4.6 mm, 5 μm) (Shimadzu, Japan) using the
mobile phase consisting of methanol/water (60/40, v/v). The peak
area correlated linearly with testosterone concentration in the range
1–100 mg/mL. The obtained linear equation is A¼73,624C –
56,654 (R2¼0.999). The coefﬁcient of variation (CV) was below
2% at three levels of 5, 25 and 100 μg/mL.
2.8.2. In vivo UPLC–MS/MS analysis of testosterone
The analyte was recovered from the plasma samples by liquid–liquid
extraction (LLE) after thawing thoroughly at room temperature.14
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serum sample as an internal standard and mixed well by vortexing, and
then LLE was performed by the addition of tert-butyl methyl ether
followed by vortex extraction for 3 min. After centrifugation at
17,800 g for 5 min, the upper organic layer was transferred into a
clean tube and evaporated to dryness at 40 1C with a vacuum
centrifugal concentrator (miVac DUO, Genevac). The residue was
reconstituted with 200 mL of mobile phase and mixed by vortexing for
30 s. Analysis of testosterone was performed with UPLC–MS/MS
system equipped with a system controller (SCL-10 ATVP; Shimadzu),
a binary pump (LC-10 ATVP; Shimadzu), a UV–Vis detector (SPD-10
AVP, Shimadzu), a column oven and an auto injector (SIL-10A;
Shimadzu) with an electrospray ionization (ESI) interface. The UPLC
separation was obtained through a C18 reversed phase analytical
column (Shim-pack XR-ODS III) (2.0 mm 75 mm, 1.6 mm) using a
mobile phase of methanol and 10 mM ammonium acetate buffer at a
ﬂow rate of 0.3 mL/min. The column temperature was set at 40 1C,
detection wavelength at 241 nm and an injection volume of 10 mL.
A gradient elution was carried out as shown in Table 3.
The MS/MS conditions were set as follows: The ionization method
was ESI, which was operated in positive single ion monitoring (SIMþ)
mode. Nitrogen was used as the nebulizer and desolvation gas with a
ﬂow rate of 3 and 15 L/min. The capillary temperature and voltage
were set at 400 1C and 3.0 kV. Desolvation temperature was 400 1C.
Quantiﬁcation was performed using the multiple reaction monitoring
mode with a transition of m/z 289.25-109.20 for testosterone and m/z
345.30-109.20 for the internal standard. The data were acquired and
analyzed by Shimadzu Labsolutions software. Retention times were
2.870.1 and 3.270.1 min for the internal standard and testosterone,
respectively. The analytical column and mobile phase used for the
assay provided a clear separation between testosterone and the internal
standard. There was no interference from any endogenous material.
The limit of detection by this method was 1 ng/mL. The method
recovery rate was 100.8071.87%, and the extraction recovery rate was
80.4573.21%. The intra-day and inter-day assay coefﬁcients of
variation were 1.89% and 3.68%, demonstrating good reproducibility.2.9. Data analysis
The cumulative amount Q (μg/cm2) of testosterone that permeated
through skin was calculated by
Qn ¼
Cn  V0 þ ∑
n1
i ¼ 1
ðCi  ViÞ
A
ð1ÞTable 3 Gradient conditions for UPLC.
Time (min) A (%)a B (%)b
0 40 60
0.5 40 60
0.8 70 30
1.5 70 30
1.8 95 5
3.0 95 5
3.2 40 60
4.5 40 60
The ﬂow rate was 0.3 mL/min.
aMethanol.
b10 mM ammonium acetate buffer.where A is the effective area, V is the volume of receptor cell, Cn is
the drug concentration at time point “n”, V0 is the volume of
receptor cell, and Ci is the testosterone concentration at time point
“i”. The cumulative amount of testosterone that permeated through
the skin was plotted versus time (h). Each data point was
expressed as the mean7SD of three determinations. The ﬂux
data were subjected to student's t-test and one-way analysis of
variance (ANOVA) to determine the level of signiﬁcance. The data
was considered to be signiﬁcant if Po0.05.
The enhancement ratio (ER) was determined using the follow-
ing equation:
ER¼ Fluxwith enhancer=Fluxwithout enhancer ð2Þ
Peak plasma concentration during the dosing period (Cmax) and
the time of peak plasma concentration (Tmax) was directly
determined from the pharmacokinetic data. The pharmacokinetic
parameters such as area under curve (AUC0 t), half-life of
elimination from plasma (t1/2) and mean residence time (MRT)
were calculated by noncompartment analysis following transder-
mal application using DAS 2.0 software. Relative bioavailability F
(%) was calculated from
Fð%Þ ¼ ðAUCoptimal formulation  doseTestopatchÞ=ðAUCTestopatch
doseoptimal formulationÞ  100% ð3Þ
The drug administration area of each pump was calculated by
Ax ¼W0  A0=Wx ð4Þ
where W0 and A0 is the known weight and area of the piece that
was clipped from the paper; Wx is the weight of the paper after
certain MDTS actuation; and Ax is the area of the pump. Taking
paper with area of 10 cm 10 cm and weighted 0.8166 g as a
sample, W0 is 0.8166 g, A0 is 100 cm
2.3. Results and discussion
3.1. Solubility
To ensure stable collection conditions, a 40% (v/v) PEG water
solution was used as the receptor ﬂuid. Based on the hypothesis
that PE acts as a “transporter vehicle” for the drug, the solubility of
testosterone in different PE can be one of the criterions for the PE
screening. The more drug solubilized in the vehicle, the higher was
the transdermal ﬂux15,16. From the results shown in Table 4, the
solubility of testosterone in different PEs is NMP4PG4azone4IPM.
NMP showed the greatest solubility for testosterone, and NMP
subsequently was used as a solubilizer in most cases. PG and azone
showed similar ability to solubilize testosterone.3.2. Preparation of MDTS
Based on the practical application of MDTS, we took 2 min as the
critical point for the drying time of the ﬁlm formed. For the
measurement of stickiness, there should not be ﬁber left on
the ﬁlm when pressing some cotton on the ﬁlm for 1 min. The
ﬁlm formed by the formulation incorporating FFP was transparent
and cohesive (Table 5). By varying the ratio of the FFP, based on
the visualization of the ﬁlm formed, we chose 5% as the content of
FFP. All formulations containing PE or both FFP and PE were
clear in appearance.
Figure 1 Percutaneous permeation proﬁles of testosterone MTDS
containing different ﬁlm-forming polymers (Mean7SD; n¼3).
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The effects of FFP, PE, testosterone concentration and the PE
content on skin permeation were investigated to optimize the
testosterone MDTS formulation.
3.3.1. Effect of FFP on skin permeation
The transdermal permeation proﬁles of formulations containing
different FFPs showed that their transdermal ﬂux is higher than
that of the control group, the ER for each formulation containing
FFP was Plasdones S6304Eudragits E PO4PVP K304Eudra-
gitsRL (Fig. 1). This might be attributed to the fact that FFP
delayed the crystallization of testosterone after its administration
and lead to greater transdermal ﬂux. These results supported the
ﬁnding that these materials had the ability to inhibit the drug
crystallization17,18.
3.3.2. Effect of PE on skin permeation
Among the PEs studied in this experiment, azone showed the
greatest transdermal ﬂux (Fig. 2). The ER for each formulation
containing PE was azone4IPM4PG4NMP. Although NMP
showed the greatest solubilizing ability for testosterone, NMP
can also be functioned as solubilizer. The solubility of testosterone
in NMP was 518.9 mg/mL, much higher than the others, which
can be attributed to this reason. Trottet et al.19 had shown that PG
would permeate though the skin and might carry the drug with it,
as shown by correlations in vitro between the permeation of both
PG and drug. The investigation of the inﬂuence of PE on drug
permeation from volatile formulations reconﬁrmed the conclusion
stated by Trottet et al. Hadgraft et al.20 reported that IPM remained
in the skin after administration to form a “patchless drug reservoir”
instead of permeating through the skin as with PG. Azone is non-
irritant to human skin, even in undiluted form, reversible in its
action and hardly absorbed through human skin21. The permeation
enhancement ability of azone was higher than IPM. Since we
found that IPM showed the greatest permeation ability during the
development of a pressure sensitive adhesive (PSA) patch forTable 4 Solubility of testosterone in different
solvents (n¼3).
Solvent Solubility (mg/mL)
Water 0.02470.007
Normal saline 0.02070.003
PBS (pH 7.4) 0.02070.005
40% PEG 200 0.32170.021
Azone 92.38072.233
NMP 518.9710.367
PG 103.074.269
IPM 6.83070.758
Table 5 Evaluation of the ﬁlm formed by MTDS incorporating FFP
FFP Appearance
Eudragits E PO Transparent
EudragitsRL Transparent
Plasdones S630 Transparent
PVP K30 Transparenttestosterone, it seems that the contradictory results suggest
different mechanisms between the two dosage forms we devel-
oped. This indicates that the solubility of testosterone in PE is a
critical factor in determination of transdermal ﬂux.3.3.3. Effect of testosterone and azone with various
concentrations
Plasdones S630 showed the greatest transdermal drug ﬂux in the
investigation of the effect of FFP on skin permeation, as shown in
Fig. 1. It almost stopped drug release during 10–24 h. While the
formulation containing azone showed continuous release during
0–24 h. This difference might be attributed to the different mechanism
which needed further investigation. So we selected formulation
containing testosterone and azone without Plasdones S630 for further
optimization. By changing the concentrations of testosterone and.
Drying time Outward stickiness
Less than 2 min No ﬁber left
Less than 2 min No ﬁber left
Less than 2 min No ﬁber left
Less than 2 min No ﬁber left
Figure 2 Percutaneous permeation proﬁles of testosterone MTDS
containing different penetration enhancers (Mean7SD; n¼3).
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responded positively with the ratio of azone when the drug is at a
relatively low concentration of 5% or 10% (Fig. 3). This might be
attributed to that the solubilized drug increased with the use of azone,
and as a result the transdermal ﬂux increased. When the drug
concentration reached a relative high level of 15%, the transdermal
ﬂux was greatest when the azone ratio was 5%, but the percutaneous
permeation proﬁles of testosterone were similar to those where the
azone ratio was 7% and 9%22,23. It may be that the azone was not able
to carry the drug into the skin fast enough after the volatile solvent
evaporated, and the crystallization of the drug outside the skin warrants
investigation24.Figure 3 Percutaneous permeation proﬁles of testosterone (a) 5%
w/v, (b) 10% w/v and (c) 15% w/v with azone content of 5%, 7% and
9% v/v (Mean7SD; n¼3).3.4. In vivo evaluation
Based on the above results, a formulation containing 10% w/v
testosterone, 9% v/v azone and 91% v/v ethanol was selected as
optimal. To compare the newly developed testosterone MDTS to
the commercial product Testopatchs in pharmacokinetic proﬁle, a
bioavailability study was carried out in female rats. Fig. 4 depicts
the proﬁles of mean plasma concentration of testosterone versus
time following the transdermal application of experimental MDTS
(100 mL, 12 cm2, 10 mg) and Testopatchs (0.5 mg/cm2, 12 cm2,
6 mg). We chose 100 mL as the dosage of experimental MDTS to
ensure the integrity of each actuation. Since the administration area
of each actuation is 12 cm2, we also delivered 12 cm2 drug
administration area for Testopatchs. The proﬁle of blank serum
sample of rats without testosterone administration was also
determined. The results indicate that plasma testosterone concen-
trations increased promptly after administration and reached the
peak level; thereafter the plasma concentrations gradually
declined. The results with the control group showed that the effect
of endogenous testosterone was limited. The pharmacokinetic
parameters were calculated using a non-compartmental model
and presented in Table 6. Compared with the testosterone MDTS
group, the Testopatchs group showed a more steady plasma
concentration proﬁle. This difference might be attributed to the
different transdermal mechanisms of these two dosage forms. In
the testosterone MDTS group, the drug reservoir was formed in the
skin after the drug administration. Once the reservoir formed, there
was no extra drug to supply for the reservoir. For the Testopatchs
group, the reservoir remained until the patch was removed. After
the peak level was reached, the testosterone in MDTS groupFigure 4 In vivo absorption proﬁles of testosterone after Testo-
patchs, testosterone MDTS and blank (mean7SD, n¼4).
Table 6 Pharmacokinetic parameters after application of the
experimental patch and Testopatchs.
Parameters (unit) Experimental patch Testopatchs
AUC0 t (ng  h/mL) 687.37798.90 517780.72
MRT0 t (h) 10.3370.72 13.7471.1
t1/2 (h) 8.8371.59 14.973.46
Tmax (h) 5.3271.31 9.0072.00
Cmax (ng/mL) 42.74714.62 27.5878.54
Data are expressed as Mean7SD, n¼4.
Table 7 Evaluation of MDTS administration area.
No. Weight (g) Area (cm2) Mean area (cm2)a
1 0.0986 12.07 11.8970.66
2 0.0898 11.00
3 0.0978 11.98
4 0.1045 12.80
5 0.0948 11.61
The statistical results of student't t-test and one-way ANOVA
showed P levels 40.05.
aData are expressed as Mean7SD, n¼5.
Table 8 Evaluation of per-actuation content for
testosterone MDTS.
Actuation times Weight per
pump (g)
Testosterone for per
pump (mg)
1–5th 0.09670.003 9.5970.11
5–10th 0.09870.002 9.7970.13
10–20th 0.10270.001 9.9770.09
20–30th 0.10270.002 9.9870.14
30–50th 0.10070.001 9.9570.12
Data are expressed as Mean7SD, n¼6.
The statistical results of a Student's t-test and one-way ANOVA
showed P levels 40.05.
W. Lu et al.398declined more quickly in the absence of a patch resevoir. The
relative bioavailability (F) was 79.78% for the testosterone MDTS.
Traditional TDDS products relied mainly on their occlusive nature
to increase the permeability of the drug candidates. Occlusion often
causes an increased possibility of skin irritation at the application
site. Occlusive systems can also provide an environment for
microbial proliferation25. Besides, manufacturing and scale-up of
multi-component patches has caused some distinct challenges to the
formulator. Additionally, issues on formulation stability and drug
crystallization on longer-term storage are still to be solved. MDTS
represents an evaporative system which provides passive and non-
occlusive delivery26. As a result of these characteristics, this system
demonstrates very low skin irritation rates. This formula also enables
the formulation a uniform distribution on the skin over a deﬁned area
after application. Comparing with the patch, the manufacturing and
scale-up of MDTS is much easier. As the MDTS is easy to use, well
tolerated and can avoid the skin irritation caused by the occlusive
environment. The advantage of this dosage form would make up its
relative low bioavailability.3.5. Characterization of the MDTS formulation
In this study, we evaluated the drug administration of each pump.
The results indicated that this MDTS formulation showed a
uniform spray pattern (Table 7).
No leakage was observed from the MDTS containers when placed
in the upright position at 301 for 3 d. Content uniformity was assessed
for the 5th, 10th, 20th, 30th and 50th doses and the results indicated
that the MDTS provides uniform content per actuation. Average weight
per metered dose is an important quantitative parameter and the
testosterone content per spray was also determined. The resultsindicated that the testosterone MDTS showed reproducible amounts
of the formulation per actuation (Table 8).3.6. Skin irritation study
No erythema or edema was found in the primary skin irritation
studies with the optimized formulations (10% testosterone, 9%
azone and 91% ethanol) on rat skin.4. Conclusions
A novel transdermal drug delivery system was designed and
evaluated in vitro and in vivo. The effects of FFPs, PEs,
testosterone concentration and the content of enhancer azone on
skin permeation were investigated to identify an optimized
formulation. The ﬁnal formulation provided satisfactory skin
permeation with an appropriate combination of testosterone and
azone content. The pharmacokinetic parameters of the optimal
formulation showed a different plasma proﬁle from that of a
commercial product, indicating a likely different transdermal
mechanism, which needs further investigation. Characterization
of the testosterone MDTS indicated that it could deliver repro-
ducible amounts of the formulation per actuation. No erythema or
edema was found in the primary skin irritation studies with the
optimized formulations in rats, and hence this application system
was found to be safe and non-irritating for transdermal application.
From the results obtained in this work it can be concluded that the
MDTS has potential as an alternative therapeutic system for the
transdermal delivery of testosterone.Acknowledgments
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